Archer primed for growth as a fabless chipmaker

Good morning,

In this edition of Archer’s Newsletter we highlight the Company’s FY23 operating and financial performance, having ended the financial year with a strong cash balance of A$23.3 million and no debt.

Archer is a technology company that operates in the semiconductor industry. We are developing two products: a qubit processor chip (12CQ) for use in quantum technologies; and a biochip that essentially creates a ‘lab-on-a-chip’ for advanced medical diagnostics.

While Archer’s quantum and biochip technology solutions are still in development phases, both made significant steps towards potential commercialisation in FY23.

As we look to the year ahead, we are focused on the exciting prospect of scaling up our quantum and biochip technologies with foundry partners in Europe, Asia, and the US, to make them more accessible for widespread integration into a broad array of applications.

Sincerely,

Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX: AXE)

Click here to view the full Newsletter